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Abstract
Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and
standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for
nearly 30–50% of patients undergoing radiotherapy. A better understanding of mechanisms that lead to radiation resistance
could aid in the development of sensitizing agents to improve outcome. Here we identified a radiation-resistance pathway
mediated by CD105, downstream of BMP and TGF-β signaling. Antagonizing CD105-dependent BMP signaling with a
partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with
irradiation. In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD105/
BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and
PGC-1α activation. Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone.
However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity
compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells. This suggested
DNA damage repair was not the sole determinant of CD105 radio-resistance. As cancer cells undergo an energy deficit
following irradiation, due to the demands of DNA and organelle repair, we examined SIRT1’s role on p53 and PGC-1α with
respect to glycolysis and mitochondrial biogenesis, respectively. Consequently, blocking the CD105-SIRT1 axis was found
to deplete the ATP stores of irradiated cells and cause G2 cell cycle arrest. Xenograft models supported these findings that
combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value= 10−9). We identified a
novel synthetic lethality strategy of combining radiation and CD105 targeting to address the DNA repair and metabolic
addiction induced by irradiation in p53-functional prostate cancers.
Introduction
Prostate cancer is the second leading cause of cancer mor-
tality in men. The standard of care for localized prostate
cancer is radiotherapy or surgical resection. Radiation is
also used as an adjuvant therapy following surgery, salvage
therapy after biochemical recurrence, and for palliation in
the setting of distant metastasis. Up to 30% of localized
prostate cancer patients treated with definitive radiation
therapy develop recurrent radio-resistant disease and the
most common anatomic site of recurrence is within the
prostate itself, even in patients at high risk of metastasis [1–
3]. Further, 50% of patients that undergo salvage radiation
therapy after biochemical recurrence will have disease
progression [4]. Although dose escalation improves bio-
chemical control, toxicity remains a significant obstacle in
optimizing local control [5, 6]. Accordingly, sensitizing
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agents are needed to improve tumor eradication and mini-
mize toxicity to normal structures. With the rational that
targeting mechanisms of radio-resistance can yield durable
sensitization, we identified a novel pathway affecting both
DNA repair and energy demands manifested by irradiation
of prostate cancer cells.
Endoglin (CD105), a type III transforming growth factor-
beta/bone morphogenic protein (TGF-β/BMP) co-receptor,
recognized as a marker of proliferating endothelia, is
upregulated in several cancers, including prostate cancer
[7]. CD105 behaves like a switch on the cell surface to
inhibit TGF-β signaling and promote BMP signaling.
Therefore, silencing or knocking out CD105 results in the
Fig. 1 Radiation-induced CD105 expression in prostate cancer cells
supports radio-resistance. a Cell surface CD105 expression was
measured in cell lines at 72 h following a dose range of irradiation (0,
2, 4, or 6 Gy). b The durability of cell surface CD105 expression in
22Rv1 was determined 0, 0.5, 4, 8, 24, 48, 72, 120, and 168 h fol-
lowing 4 Gy irradiation. CD105 cell surface expression fold change
was normalized to levels expressed prior to irradiation. c The mRNA
expression of CD105 ligands was measured at 0, 4, and 8 h post
radiation by rtPCR. Expression was normalized to GAPDH and to the
0 h time point. d Western blot for phosphorylated Smad1/5 was
measured in 22Rv1 cells in the presence or absence of serum starva-
tion and treatment with 50 ng/ml BMP4 or TRC105. β-actin expres-
sion served as the loading control. Molecular weight (kDa) is
indicated. e Annexin-V expression was measured in 22Rv1 cells by
FACS analysis 5 days following 4 Gy irradiation and treatment of IgG
or TRC105. f Clonogenic assay was measured 10 days following
irradiation of 22Rv1 and C4-2B cells in a dose range of 0–6 Gy in the
presence of IgG or TRC105. Data are reported as a mean ± S.D. of
three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001
compared to control, unless otherwise indicated)
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gain of TGF-β-mediated Smad2/3 signaling and loss of
Smad1/5 signaling associated with BMP activity [8].
CD105 expression on various cancers has correlated with
progression, metastasis, aggressiveness, and evasion to
conventional therapeutics [9–12]. Various DNA repair
genes were found to be downregulated by CD105 silencing,
thereby sensitizing ovarian cancer to DNA a damaging
agent, cisplatin [13]. However, these studies did not dis-
tinguish between the CD105 effects on TGF-β and BMP
signaling on DNA damage repair. Significant data are
reported for the use of specific TGF-β inhibition in radiation
sensitizing breast cancer and glioblastoma [14, 15]. How-
ever, limited information is known about the role of BMP
signaling in response to radiation. In this study, we use
TRC105, a partially humanized monoclonal antibody that
blocks the CD105/BMP signaling complex. Importantly, as
TRC105 does not affect the CD105/TGF-β signaling axis,
the role of CD105/BMP signaling on radiation respon-
siveness was tested [16]. Based on our finding that CD105
was elevated by irradiation, we hypothesized targeting
CD105, using TRC105, could sensitize prostate cancer to
irradiation. Of note, numerous phase I trials have shown
TRC105 to be well tolerated, but it has had limited ther-
apeutic efficacy for prostate cancer as a single agent [17,
18].
Probing CD105/BMP regulation of DNA repair genes
led us to identify sirtuin 1 (SIRT1), a NAD+-dependent
histone deacetylase, as a BMP-regulated target. SIRT1
activation is observed in prostate cancer and in response to
irradiation [19]. In the context of cancer, SIRT1 has been
studied primarily for its role in DNA damage response.
Outside of cancer biology, SIRT1 de-regulation is asso-
ciated with metabolic, neurodegenerative, and cardiovas-
cular diseases [20–22]. SIRT1 has both tumor suppressor
and oncogenic properties [23]. Apart from histones, SIRT1
regulates p53 and peroxisome proliferator-activated recep-
tor gamma co-activator 1-alpha (PGC-1α) [22, 24, 25].
SIRT1-mediated deacetylation contributes to p53 de-
stabilization. Accordingly, blocking SIRT1 in prostate
cancer is reported to stabilize p53 leading to the inhibition
of glycolysis [26]. Further, SIRT1 potentiates PGC-1α
transcriptional activity in promoting mitochondrial biogen-
esis and oxidative phosphorylation [21]. With the rational
that irradiation elevates the energy needs of a cell to enable
DNA and organelle repair for cell recovery [27], targeting
metabolic pathways could mediate radiation resistance. We
tested the role CD105 has on the acute effects on DNA
damage repair as well as its chronic energy needs down-
stream of a new target, SIRT1, in the context of irradiation.
Results
CD105 expression in prostate cancer upon radiation
CD105 is implicated in resistance to therapy in several
cancers, including ovarian, gastric, and breast cancer [13,
28, 29]. Fluorescence-activated cell sorting (FACS) analysis
revealed that prostate cancer cell lines, PC3, C4-2B, and
22Rv1, upregulate cell surface CD105 expression when
exposed to irradiation (Fig. 1a). Expression of cell surface
CD105 was both radiation dose- and time-dependent (Fig.
1b). While 2 Gy radiation did not significantly upregulate
CD105 expression, doses of 4 and 6 Gy significantly
increased CD105 for all three cell lines. Further, CD105
expression in 22Rv1 showed a significant elevation by 8 h
after 4 Gy radiation that persisted for at least 1 week. As
CD105 can facilitate signaling by interacting with a number
of different ligands, we next tested for the expression of a
panel of TGF-β/BMP ligands post radiation. We found a
significant elevation of BMP4, BMP6, BMP9, TGF-β1,
TGF-β2, Activin A, and LRG1 by irradiation (Fig. 1c).
Next, we sought to identify the role of CD105/BMP
signaling in prostate cancer radiation response by blocking
BMP-dependent CD105 signaling using TRC105. To con-
firm the ability of TRC105 in modulating BMP signaling,
we analyzed phosphorylation of SMAD1/5 and the
expression of ID1, a BMP target gene, in 22Rv1 stimulated
with BMP4 under serum-free conditions (Fig. 1d, Supple-
mental Fig. 1). A known BMP antagonist, noggin, was used
to confirm BMP-dependent regulation of ID1 expression by
TRC105. Importantly, TRC105 did not affect TGF-β-
dependent expression of COL1A1, while the TGF-β inhi-
bitor LY-364947 effectively inhibited TGF-β induction of
COL1A1 (Supplemental Fig. 1). Combining TRC105 with
radiation significantly increased apoptosis as measured by
cell surface Annexin-V expression, compared to radiation
alone (p value < 0.01, Fig. 1e). To determine if CD105
confers radio-resistance, clonogenic survival assays were
performed comparing IgG- or TRC105-treated 22Rv1 and
C4-2B cell lines with increasing doses of radiation (Fig. 1f).
In both these cell lines, treatment with TRC105 sensitized
prostate cancer cells to radiation (p value < 0.001). Toge-
ther, radiation-induced CD105 seemed to regulate prostate
epithelial cell death and clonogenicity.
Radiation-induced BMP mediates SIRT1-dependent
DNA damage repair
The upregulation of CD105 by irradiation and its potential
consequence on cell death suggested that CD105 may be
involved in the DNA damage response. To test if impaired
of DNA damage repair is the mechanism by which TRC105
conferred radio-sensitivity, γ-H2AX and p53-binding
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protein (53BP1) foci quantitated following 4 Gy radiation.
Combined, irradiation and TRC105 treatment resulted in a
significant elevation in γ-H2AX and 53BP1 foci 4–24 h
post irradiation, compared to irradiation and IgG control
(Fig. 2a). However, by 48 h post irradiation, there were no
significant differences in DNA double-stranded breaks
between the experimental groups (data not shown). The
alkaline comet assay provided a measure of single-stranded
DNA breaks induced by irradiation in the presence and
absence of TRC105. There was a significant increase in tail
moment of TRC105-treated cells 30 min following irradia-
tion compared to radiation plus IgG (p value < 0.001), but
there was no difference between the two groups after 24 h
(Fig. 2b). Antagonizing BMP signaling downstream of
CD105 by TRC105 administration impaired the repair of
both double- and single-stranded DNA damage mediated by
irradiation, to suggest CD105 as a target for radiation
sensitivity.
To better understand the observed longer-term effects of
radiation in the presence of TRC105, we examined the
expression of DNA repair genes following 4 Gy irradiation.
As expected, double-stranded DNA repair genes (PARP1
and XRCC1) and the base excision repair genes (NEIL1 and
OGG1) were back to baseline levels 72 h following irra-
diation as most DNA damage had been repaired (Fig. 2c).
Interestingly, SIRT1, a critical DNA damage repair com-
ponent with deacetylase activity was found to be elevated
approximately sixfold by irradiation over control (p value <
0.0001) and nearly restored to control levels by TRC105
72 h after irradiation (Fig. 2c). Similar SIRT1 mRNA
expression patterns were observed with C4-2B cells (Sup-
plemental Fig. 2a). SIRT1 was found to be significantly
Fig. 2 TRC105 induces transient DNA damage and repression of
SIRT1 induction. 22Rv1 were pre-treated with IgG or TRC105 24 h
prior to irradiation with 4 Gy. a γ-H2AX or 53BP1 were immunolo-
calized at 4 and 24 h post irradiation. Foci per nuclei were quantified
(n= 100). Representative images are shown for γ-H2AX (green) and
53BP1 (green) foci, nuclear counterstained with DAPI (blue). b Comet
assay was performed 30 min and 24 h following irradiation. The tail
moment was quantified (n= 50). c The mRNA expression of DNA
damage repair genes were measured by rtPCR 72 h post irradiation. d
SIRT1 mRNA expression was measured in a time course 0–72 h fol-
lowing 4 Gy irradiation of 22Rv1. SIRT1 mRNA expression was
normalized to GAPDH and to untreated. Data are reported as a mean ±
S.D. of three independent experiments (***p < 0.001, ****p < 0.0001,
NS not significant, compared to control)
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upregulated in a time-dependent and radiation dose-
dependent manner in both 22Rv1 and C4-2B cells at the
mRNA and protein levels (Fig. 2d and Supplemental Fig.
2b-e). Unlike the other DNA damage repair genes that are
acutely active following irradiation, SIRT1 is chronically
expressed in irradiated prostate cancer cells.
The role of SIRT1 in tumors has long been contentious
as it has been shown to act as both a tumor suppressor as
well as tumor promoter [23]. Therefore, we sought to
compare SIRT1 levels in patient samples to determine its
role in prostate cancer. Using R2-Genomics analysis, we
compared SIRT1 expression in patient samples from the
German Cancer Research Center and National Center of
Tumor Diseases Affymetrix GeneChip exon array dataset
with benign tissue (n= 48) and prostate cancer tissue (n=
47) [30]. The comparison validated SIRT1 expression was
Fig. 3 Radiation induces BMP-mediated SIRT1 expression. a Fold
change of SIRT1 mRNA in benign prostate and prostate cancer
patients, obtained from R2-Genomics analysis is expressed (n= 95). b
SIRT1 mRNA expression was measured in 22Rv1 under serum-free
conditions with 50 ng/ml BMP4, in the context of increasing doses of
TRC105 (0.05, 0.1, 0.5, 1, 5, or 10 µg/ml) or with 50 ng/ml noggin.
SIRT1 mRNA expression was normalized to GAPDH and to serum-
treated control. c Western blot for phosphorylated Smad1/5, SIRT1,
and β-actin expression was measured in 22Rv1 cells following serum
starvation and treatment with 50 ng/ml BMP4. Densitometric quanti-
tation is indicated under each band. d SIRT1 and p21 protein
expression was measured 72 h after irradiating (4 Gy) 22Rv1 and PC3
cells in the presence of IgG or TRC105 prior to irradiation. e γ-H2AX
(green) was immunolocalized in PC3 cells following treatment with
IgG, TRC105, and 4 Gy irradation at 4 h. Cells were nuclear coun-
terstained with DAPI (blue). Foci per nuclei were quantified (n= 100)
(****p < 0.0001 as compared to control). f Clonogenic survival assay
was performed on p53-null PC3 cells at indicated doses of radiation.
No significant (NS) radiation sensitization was had with TRC105
compared to IgG control. mRNA expression are reported as a mean ±
S.D. (**p < 0.01, ***p < 0.001, ****p < 0.0001, compared to control)
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significantly upregulated in prostate cancer samples (p
value < 0.0001, Fig. 3a). Since blocking CD105/BMP sig-
naling with TRC105 resulted in limiting radiation-induced
SIRT1 expression, we investigated the role of BMP4 on
SIRT1 expression. We found antagonizing CD105 with
TRC105 effectively blocked BMP4-dependent induction of
SIRT1 in a TRC105 dose-dependent manner, similar to that
mediated by noggin (Fig. 3b). Strikingly, the BMP4-
induced SIRT1 protein expression in serum-starved 22Rv1
associated with phosphorylated SMAD1/5 (Fig. 3c), sug-
gesting a role for CD105 in the regulation of SIRT1 via
canonical BMP signaling.
SIRT1 expression is a known result of radiation treat-
ment. We found that CD105/BMP signaling is necessary
and sufficient for SIRT1 expression downstream of radia-
tion treatment, as TRC105 limited radiation-induced SIRT1
protein expression (Fig. 3d). Interestingly, both 22Rv1 and
p53-null PC3 cells similarly induced SIRT1 in a CD105-
dependent manner. However, the lack of p53 in PC3 dis-
abled p21 induction by TRC105 treatment, observed in
22Rv1 cells. This suggested CD105/BMP inhibition of p21
was p53-dependent. However, SIRT1 is known to de-
stabilize p53 by de-acetylating p53-K382. Thus, to test
SIRT1 function downstream of CD105, we measured p53
regulation by immuno-precipitation and immunoblotting for
acetylated p53-K382 following treatment with either
TRC105 or nicotinamide, an inhibitor of SIRT1 activity, in
the context of radiation. As expected, radiation alone
resulted in increased total p53 expression compared to
control. Inhibiting SIRT1 expression with TRC105 resulted
in elevated p53 acetylation and total p53 expression, com-
pared to radiation alone (Supplemental Fig. 3a). Irradiation-
induced CD105 mediated SIRT1 expression and function as
revealed by suppressed p53 expression.
The apparent SIRT1 regulation of p53 by CD105/BMP
signaling prompted us to test the efficacy of TRC105-
mediated radiation sensitization in PC3 cells. Yet, in PC3
cells, TRC105 caused significantly elevated DNA double-
stranded breaks following irradiation, compared to IgG
control (Fig. 3e). However, when we knocked down p53 in
22Rv1 (siP53), TRC105 did not further γ-H2AX foci
numbers significantly compared to scrambled siRNA or IgG
controls (Supplemental Fig. 3b, c). Accordingly, in clono-
genic assays treating PC3 with TRC105 at increasing doses
Fig. 4 PGC-1α and mitochondrial biogenesis are regulated by CD105/
BMP. 22Rv1 cells were incubated with IgG or TRC105 with or
without 4 Gy irradiation. All measurements were made 72 h post
irradiation. a Western blot for whole-cell lysate, nuclear, and cyto-
plasmic fractions were independently analyzed for PGC-1α expres-
sion. Loading controls included β-actin (whole cell), lamin B (nuclear
marker), and Rho A (cytoplasm marker). Molecular weights (kDa) of
the ladder are indicated. b Immunofluorescent localization of PGC-1α
(green) was visualized with DAPI (blue) nuclear counterstain. c The
mRNA expression of PGC-1α target genes, NRF1,MTFA, and CPT1C
were measured. MRNA expression was normalized to GAPDH and
untreated. d Mitochondrial DNA (mtDNA) was measured from total
DNA extracts and normalized to nuclear DNA and to untreated. Data
are reported as means ± S.D. of three independent experiments (**p <
0.01, ***p < 0.001, compared to control unless otherwise indicated)
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of radiation did not provide radiation sensitization over IgG
control (Fig. 3f). PC3 cells have previously been described
as unresponsive to SIRT1 inhibitors [24]. While loss-of-
function p53 mutations are rare in prostate cancer, 50–75%
of pancreatic cancers have p53 mutations [31, 32]. We
therefore tested two p53 mutant pancreatic cancer cell lines,
MIAPACA-2 and HPAF-II, for radiation responsiveness in
the context of TRC105 treatment. In validating the findings
with PC3 cells, neither MIAPACA-2 nor HPAF-II were
sensitized to radiation by CD105 antagonism (Supplemental
Fig. 3d, e). This suggested the novel CD105-SIRT1 sig-
naling axis requires p53 for radiation responsiveness.
PGC-1α and cellular energy production are
regulated by CD105/BMP
Cell recovery from radiation-induced damage requires large
amounts of energy. Further, radio-resistant cancer cells have
been shown to induce mitochondrial content and mito-
chondrial DNA (mtDNA) accumulation in response to
radiation [33]. Therefore, we reasoned that targeting cellular
metabolism may play a role in the radiation sensitization
seen with TRC105 and its inhibition of radiation-induced
SIRT1 upregulation. We tested another downstream func-
tion of SIRT1, the activation of PGC-1α, a transcription
factor involved in mitochondrial biogenesis. Activation and
nuclear localization of PGC-1α requires deacetylation by
SIRT1 [21]. The treatment of 22Rv1 cells with 4 Gy
radiation in the presence of IgG or TRC105 had no effect on
PGC-1α expression, by western blotting of the whole-cell
lysate (Fig. 4a). However, closer examination of subcellular
localization through organelle fractionation demonstrated
PGC-1α depletion from the cytoplasmic fraction and
accumulation in the nuclear fraction in the context of
radiation. Blocking CD105 prevented radiation-induced
nuclear translocation of PGC-1α. Immunofluorescent loca-
lization corroborated these same findings (Fig. 4b). PGC-1α
target genes involved in oxidative stress, mitochondrial
biogenesis, and fatty acid oxidation: NRF1, MTFA, and
CPT1C, respectively, were significantly elevated by
Fig. 5 Metabolic changes induced by CD105 antagonism. a, b Cells
were analyzed for mitochondrial activity 168 h following 4 Gy irra-
diation in the presence of IgG or TRC105. a Basal respiration, non-
mitochondrial respiration, mitochondrial ATP, spare respiratory
capacity, and b extracellular acidification rate were quantitated. Data
are reported as mean ± S.D. of a representative experiment (n= 5) of
three independent experiments. c Total cellular ATP was measured 0,
24, 72, 120, and 168 h following 4 Gy irradiation in the context of IgG,
TRC105, or nicotinamide treatment. Data are reported as mean ± S.D.
of three independent experiments (**p < 0.01, ***p < 0.001, ****p <
0.0001). d Cell cycle analysis was performed on 22Rv1 at 0, 4, 8, and
24 h post irradiation in the presence of IgG or TRC105 (n= 3) in three
independent experiments
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radiation (p value < 0.001, Fig. 4c). The same genes were
significantly downregulated by the added treatment with
TRC105 in both 22Rv1 and C4-2B cells (Fig. 4c and
Supplemental Fig. 4a). Consequently, mtDNA content was
significantly elevated by irradiation (p value < 0.0001), to
be restored to control levels by antagonizing CD105 (Fig.
4d). The evaluation of specific mitochondrial electron
transport chain proteins showed TRC105 treatment down-
regulated complex I-NDUF88 and complex IV-MTCO1
(Supplemental Fig. 4b). To further validate the importance
of PGC-1α in TRC105-mediated radiation sensitization, we
knocked down PGC-1α in 22Rv1 and measured γ-H2AX
(Supplemental Fig. 4c). Silencing of PGC-1α resulted in a
significant increase in radiation-induced γ-H2AX foci per
nuclei, indicating mitochondrial biogenesis was necessary
for DNA damage repair. Together, we found that CD105
regulation of SIRT1 expression affected both DNA damage
and maintenance of mitochondrial integrity through PGC-
1α in the context of irradiation.
Since PGC-1α was crucial for DNA damage repair, we
studied the functionality of the mitochondria after radiation
and TRC105 treatment through the measurement of oxygen
consumption rates (OCRs) as an indicator of oxidative
phosphorylation activity. Radiation treatment elevated non-
mitochondrial respiration compared to cells not irradiated,
regardless of TRC105 treatment (Fig. 5a). However, when
comparing only mitochondrial respiration, the basal oxygen
consumption of irradiated to non-irradiated cells was simi-
lar. Not surprisingly, radiation-mediated mitochondrial
damage manifested in decreased ATP production and a
depletion of spare respiratory capacity. Antagonizing
CD105 in the context of radiation resulted in a decrease in
basal oxidative phosphorylation, further decrease in ATP
production, and spare respiratory capacity compared to
radiation alone. Mitochondrial ATP production down-
regulated by irradiation was found to increase reliance on
glycolysis, as measured by extracellular acidification rate
(ECAR), in 22Rv1 cells (Fig. 5b). But, further addition of
TRC105 inhibited glycolysis in 22Rv1 cells.
Glycolysis and oxidative phosphorylation are crucial for
energy production in the form of ATP. We found a sig-
nificant depletion of cellular ATP stores within 1 day of
Fig. 6 Antagonizing CD105
confers radio-sensitivity in vivo.
a Tumor volumes were
longitudinally measured. When
tumor average volume reached
80 mm3 mice were treated with
IgG or TRC105 (T) in the
context of radiation (2 Gy for
5 days). Tumors were harvested
15 days after the first dose of
radiation (n= 6). b Tumor
volume fold change was
normalized to the first dose of
radiation (†p= 1 × 10−9). Each
treatment was compared for
doubling of tumor volume as a
function of time as depicted in
the cumulative incidence plot. d
Histochemical localization of
SIRT1, phosphorylated histone
H3, and survivin was performed
on paraffin-embedded tumor
tissues. Phosphorylated histone
H3 and survivin expression was
quantitated as a measure of total
cells per field per tumor (**p <
0.01, ***p < 0.001)
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radiation treatment (p value < 0.01), which seemed to be
restored to levels close to control by 3 days in 22Rv1 cells
(Fig. 5c). When SIRT1 expression was inhibited by CD105
antagonism or its function with nicotinamide, cellular ATP
stores were significantly lower than the non-irradiated
control and further depleted by irradiation. The reliance of
intact p53 for TRC105 radio-sensitization suggested inhi-
bition of glycolysis by p53 is critical to radio-sensitization
[34, 35]. To independently test the consequence of ATP
derived from oxidative phosphorylation on cell prolifera-
tion, 22Rv1, siP53 22Rv1, and p53-null PC3 cells were
treated with oligomycin, an ATP synthase inhibitor. 22Rv1
proliferation limited by irradiation was further down-
regulated by oligomycin (p value < 0.01, Supplemental Fig.
5). In contrast, the PC3 cells, had reduced cell counts with
irradiation by about 50%, but were insensitive to inhibition
of mitochondrial ATP synthesis. Silencing of p53 resulted
in reduced susceptibility of 22Rv1 to oligomycin treatment
than scrambled siRNA. Silencing of p53 was not as robust
as PC3 response to oligomycin, possibly due to incomplete
silencing or long-term metabolic adaptation of p53 loss in
PC3. Hence, the p53 response is important for radiation-
induced maintenance of energy homeostasis and cell
division.
The impact of radiation on the cell cycle is well descri-
bed as causing a G2 cell cycle arrest followed by cell cycle
redistribution. In view of the fact that both p53-dependent
p21 activity and mitochondrial dysregulation can similarly
impact G2 cell cycle arrest [36–38], we found that irra-
diating 22Rv1 cells, in the presence of IgG, caused an
accumulation of cells in G2 phase by 4 h, to then recover to
control levels by 8 h (Fig. 5d). Interestingly, TRC105 alone
expanded the G2 cell population. The combination of
radiation and TRC105 treatment resulted in G2 cell cycle
arrest that did not resolve by 24 h. Therefore, radiation-
induced CD105 signaling helps restore metabolic activity
chronically to enable the G2/M cell cycle transition.
Antagonizing CD105 confers radio-sensitivity in vivo
Lastly, we tried to determine the role of CD105 on radio-
resistance using a 22Rv1 xenograft model. Mice engrafted
with 22Rv1 were given one dose of IgG or TRC105 72 h
prior to irradiation when the tumor reached 0.8 cm3. The
tumors were irradiated (2 Gy) for 5 consecutive days and
TRC105 was administered 3 times a week for the duration
of the treatment schedule (Fig. 6a). We found TRC105
alone did not influence tumor volume compared to the
control IgG treated group (Fig. 6b). The tumor volumes for
the irradiated IgG group was significantly lower a week
after irradiation compared to control, but by 2 weeks this
group was not significantly different from the non-irradiated
groups. Conversely, the combination of radiation- and
TRC105-treated tumor volume was dramatically lower than
the other three experimental groups (repeated measures
analysis of variance (R-ANOVA) p value= 1 × 10−9 and F-
statistic of 11.4). The tumor-doubling time was appreciably
reduced by combining TRC105 with irradiation compared
to either treatment alone. Immunohistochemical staining of
the tumors showed a radiation-induced increase in SIRT1,
abrogated by the treatment with TRC105 (Fig. 6c). The
mitotic index measurement by phosphorylated histone H3
quantitation indicated a significant downregulation by the
combination of TRC105 and irradiation (p value= 0.0002).
Fig. 7 A Schematic depiction of the mechanism of CD105/BMP sig-
naling in conferring radiation resistance. Radiation of prostate cancer
results in upregulation of cell surface CD105 expression. The ensuing
CD105/BMP signaling is essential and necessary for SIRT1 expres-
sion and downstream activity. SIRT1 facilitates DNA damage repair,
destabilizes p53, and activates of PGC-1α in response to radiation.
Consequently, CD105 can regulate glycolysis and mitochondrial bio-
genesis to meet the higher energy demands necessary for survival
following irradiation. The loss of functional p53 enables glycolysis as
a source of ATP generation and survival
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Concomitantly, the expression of survivin, an anti-apoptotic
protein, was also markedly decreased in irradiated tumors
treated with TRC105 (p value= 0.002). Thus, mitigating
radiation-elevated CD105-induced SIRT1 by TRC105 is an
effective radiation sensitizer for p53-intact prostate cancer.
Discussion
Our work demonstrates the role of CD105 upregulation in
response to irradiation. Most of what is known about
CD105 signaling has been elucidated from studying endo-
thelial cells and vascular diseases characterized by CD105
mutations such as hereditary hemorrhagic telangiectasia and
preeclampsia. In endothelia, CD105 expression is tightly
regulated by hypoxia inducible factor-1 alpha (HIF-1α)
[39]. Since radiation induces HIF-1α, an increase in CD105
expression with radiation treatment was anticipated [40].
Instead of performing studies where CD105 is silenced or
knocked out, as others have done in the context of DNA-
damaging chemotherapy studies [13], we deliberately used
a neutralizing antibody that inhibited the CD105/BMP
signaling axis without affecting TGF-β signaling. In breast
cancer, radiation causes an increase in serum TGF-β levels
and inhibiting tumor TGF-β signaling can sensitize to
radiation [15, 41, 42]. The mechanism of TGF-β inhibition-
associated radiation sensitization is primarily associated
with impaired DNA damage repair [42]. Thus, knocking out
CD105 would achieve BMP signaling inhibition, but would
activate TGF-β signaling—not a desired outcome. We
found inhibiting BMP signaling through TRC105 or noggin
could inhibit SIRT1 expression. We identified a new role
for CD105 in mediating metabolic adaptations to stress
caused by radiation through the regulation of a novel
CD105/BMP target, SIRT1 (Fig. 7). SIRT1 inhibitors have
been effective in sensitizing a variety of cancer cell lines to
DNA-damaging agents, including radiation. However, the
mechanism by which SIRT1 inhibitors, such as nicotina-
mide, sensitize cancers to therapy has largely been attrib-
uted to SIRT1’s role in DNA damage repair. We show that
suppressing SIRT1 expression by antagonizing CD105/
BMP signaling leads to increased DNA damage with
radiation acutely (Fig. 2), exacerbated by severe depletion
of energy chronically (Fig. 5).
The induction of CD105 by radiation in the tumor epi-
thelia is exploited by the administration of TRC105. As a
tool to interrogate the mechanism of action, TRC105
demonstrated that effective radiation sensitizers do not
necessary need to solely act as DNA damage effectors. In
addition to the capacity of the BMP-CD105-SIRT1 signal-
ing axis to support DNA repair downstream of p53, we
demonstrated it conferred radio-resistance through the
induction of mitochondrial biogenesis through PGC-1α
activity. TRC105, as a single agent, has little impact on cell
proliferation despite its inhibitory effects on mitochondrial
biogenesis and glycolysis, as the energy needs of a non-
irradiated cells are minimal. However, the added ATP
requirement to repair radiation-induced damage makes
mitochondrial biogenesis obligatory following irradiation.
Prostate cancer cells respond to irradiation by increasing
SIRT1 expression (Fig. 2) to transiently increase glycolysis,
by stabilizing p53 (Fig. 3), and mitochondrial biogenesis,
by potentiating PGC-1α activity (Fig. 4), to sustain
immediate and long-term energy requirements (Fig. 5) [20,
34]. Antagonizing CD105 with TRC105 acts by acutely
limiting DNA damage repair and chronically preventing
recovery by depleting their energy stores, thereby limiting
prostate cancer expansion. PARP1 inhibitors have been
effective radio-sensitizers for prostate and other cancers by
furthering DNA damage accumulation. Unlike for PARP1
inhibitors, intact p53 function was necessary for TRC105-
mediated radio-sensitization. TRC105 exploits the meta-
bolic addiction induced by radiation in p53-intact cells.
Addressing the CD105-mediated radiation resistance
mechanism with TRC105 can serve as a synthetic lethal
strategy for patients on radiotherapy.
Materials and Methods
Cell lines and culture
CWR22Rv1 (22Rv1), PC3, C4-2B, MIAPACA-2, and
HPAF-II cells were purchased (American Type Culture
Collection). Cell lines were cultured in RPMI-1640 medium
in 10% fetal bovine serum. For counting cells for pro-
liferation, 25 000 cells/24 wells were treated with oligo-
mycin 1 h before radiation. Cells were collected and
counted using a hemocytometer 72 h post treatment using 5
wells per treatment. The Gammacell 40 Exactor (Best
Theratronics, Ottawa, CA) was used for irradiation at
indicated doses. 22Rv1 were silenced using pooled target-
specific 19- to 25-nucleotide siRNAs by transfecting with
either control siRNA-A (sc-37007, Santa Cruz Bio-
technology), PGC-1α siRNA (sc-38884, Santa Cruz Bio-
technology), or P53 siRNA (sc-29435, Santa Cruz
Biotechnology). Cells were transfected using Lipofectamine
3000 Reagent (ThermoFisher) according to the manu-
facturer’s protocol.
Reagents
TRC105 was provided from TRACON Pharmaceuticals,
Inc. Cells were treated with TRC105 at a concentration of 1
µg/ml, unless noted otherwise. BMP4 (PHC9534, Gibco)
and noggin (120-10 C, Peprotech) were used at 50 ng/ml.
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TGF-β was used at 5 ng/ml and LY-364947 was used at 10
µM. Nicotinamide was used at 200 µg/ml. Oligomycin
(495455, EMD Milipore) was used at 1, 1.5, 2, and 2.5 µM
concentrations for proliferation assays.
Clonogenic survival assay
Cells were seeded 2 h prior to irradiation and treated with
either IgG or TRC105. Cells were grown for 7–10 days to
allow for colony formation and then fixed and stained with
crystal violet in methanol. Colonies were delineated as <50
cells. Survival fraction was calculated as the ratio of the
number of colonies formed to the number of colonies see-
ded times the plating efficiency [43].
Immunofluorescence
Cells grown on coverslips were fixed with 4% paraf-
ormaldehyde at room temperature followed by phosphate-
buffered saline (PBS) rinses. Cells were permeabilized and
blocked with 0.1% Triton X-100 and 1% bovine serum
albumin in PBS for 1 h at room temperature, followed by
incubation with γ-H2AX (05-636, EMD Millipore), 53BP1
(SC-22760, Santa Cruz Biotechnology), or PGC-1α (SC-
13067, Santa Cruz Biotechnology) antibodies at 4 °C. Alexa
488 anti-mouse and Alexa 488 anti-rabbit (Life Technolo-
gies) secondary antibodies were used at room temperature.
Coverslips were mounted with Vectashield Hardset Anti-
fade Mounting Medium with DAPI (H-1400, Vector
Laboratories). Images were taken with Olympus FSX-100
and quantitated as foci per nuclei using ImageJ.
Alkaline Comet assay
Cells were collected at indicated time points and re-
suspended in low-melting-point agarose provided by Cell
Biolabs’s COMET Assay kit (STA-351, Cell Biolabs). The
assay was run per the manufacture’s protocol. Images were
taken using an Olympus FSX-100 microscope and quanti-
tated using the OpenComet plugin for ImageJ.
FACS analysis
FACS experiments were performed with anti-human
CD105-APC (17-1057-41, e-Biosciences) and anti-human
Annexin-V-PE (BDB556422, BD Biosciences). Cell cycle
was analyzed as previously reported [44]. All events were
acquired on a BD Accuri C6 Plus flow cytometer and
analyzed by FlowJo software v10.2.
Protein analysis
Whole-lysate western blots were probed for the following
antibodies phos-SMAD1/5 (9516, Cell Signaling Technol-
ogies), SIRT1 (9475, Cell Signaling Technologies), p21
(4060, Cell Signaling Technologies), PGC-1α (ST1202,
EMD Millipore), Total OXPHOS Rodent (ab110413,
Abcam), PGC-1α (ST1202, EMD Millipore), lamin B (sc-
6217, Santa Cruz Biotechnology), Rho A (sc-418, Santa
Cruz Biotechnology), p53 (sc-126, Santa Cruz Bio-
technology), K382 acetyl-p53 (2525, Cell Signaling Tech-
nologies), and β-actin (sc-47778, Santa Cruz
Biotechnology). The NE-PER Nuclear and Cytoplasmic
Extraction Reagent Kit (PI-78833, Thermo Scientific) was
used according to protocol. To enrich for p53, samples were
immunoprecipitated using p53 N-term-Trap (pta-20, Chro-
motek) according to the manufacter’s protocol with addition
of 200 µg/ml of nicotinamide to lysis and wash buffers.
Quantitative real-time PCR
RNA was extracted using the RNeasy mini kit (74106,
Qiagen Inc.) according to the manufacturer’s protocol.
Reverse transcription and quantitative real-time PCR data
were calculated by ΔΔCt method and represented relative to
18S rRNA expression. mtDNA was quantified as previously
described using MTCO2 expression normalized to genomic
ACTB expression [45]. (Refer to Supplemental Table 1 for
primer sequences.)
Oxygen consumption and acidification analysis
Respirometry was conducted on 22Rv1 cells using the
Seahorse XFe24 Extracellular Flux Analyzer (Seahorse
Biosciences) 7 days after radiation treatment for real-time
measurements of OCR and ECAR (as a reporter of glyco-
lysis). Cells were seeded in XF24 cell culture plates at a
density of 100 000 cells/well and assay was conducted 16 h
after. Prior to performing the assay, culture media was
exchanged for Seahorse XF Base media (supplemented to
10 mM glucose, 1 mM pyruvate, and 1 mM glutamine, pH
7.4) and equilibrated for 1 h at 37 °C in a non-CO2 incu-
bator. Final concentration of inhibitors are as follows: 2 μM
oligomycin; 1.5 μM FCCP (carbonyl cyanide 4-(tri-
fluoromethoxy)phenylhydrazone), 1 μM antimycin A; and
1 μM rotenone (Sigma). Results were normalized to protein
concentration determined by Pierce BCA Protein Assay Kit.
ATP assay
22Rv1 cells were collected at days 0, 1, 3, 5, and 7 after
radiation and pellets were frozen. ATP was quantified
immediately after lysis of pellets using the ATP
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Determination Kit (A22066, Invitrogen) according to the
manufacturer’s protocol.
Xenograft model
22Rv1 (1 × 106) were suspended in 100 µl of saline with
50% rat-tail collagen and were implanted subcutaneously
into the flank of 6-week-old male athymic nude mice
(Envigo, Indianapolis, IN). N= 6 mice were used per a
condition, based on previous subcutaneous tumor experi-
ments. When average tumor volume reached 80 mm3, the
mice were placed into four groups (IgG alone, TRC105
alone, IgG with radiation, and TRC105 with radiation) by
randomization and the first dose of TRC105 or IgG was
administered. Mice were treated with either IgG or TRC105
(50 µg) three times a week, unblinded. Tumor volume was
recorded three times a week with digital calipers. No ani-
mals were excluded from analysis. All animal experiments
were performed in accordance with the guidelines of the
Institutional Animal Care and Use Committee at Cedars-
Sinai Medical Center.
Immunohistochemistry
Paraffin-embedded tissues (5 μm thick) were subjected to
immunohistochemical staining as previously reported [46].
Anti-phosphorylated histone H3 (PH-H3, 06-570, Milli-
pore), anti-survivin (2808, Cell Signal Technologies), and
anti-SIRT1 (sc-74504, Santa Cruz Biotechnology) were
incubated at 4 °C overnight. Secondary antibody develop-
ment was performed with Dako Cytomation EnVision+
mouse or rabbit labeled polymer kits (K4001 and K4003,
Dako Cytomation) and visualized using 3,3′-diamino-
benzidine tetrahydrochloride substrate (K3468, Dako
Cytomation). Up to five fields per tissue (n= 4) were
quantitated with Fiji (ImageJ) using a custom-written
macro. Mitotic (PH-H3) index was calculated by taking
the total number of positive (brown) nuclei divided by the
total number of nuclei.
Statistical analysis
Student’s T-test was used to compare radiation alone to
radiation with treatment. Two-way ANOVA was used to
compare the effect of multiple treatment groups. The R-
ANOVA in MATLAB was used to calculate the p values
for detecting tumor size differences over time. Results were
expressed as individual data points or as the mean ± S.D. p
values of <0.05 were considered statistically significant (*p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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